Secukinumab Provides Sustained Improvements in the Signs and Symptoms of Active Psoriatic Arthritis through 3 Years: Efficacy and Safety Results from a Phase 3 Trial

Mease PJ, Kavanaugh A, Reimold A, Tahir H, Rech J, Hall S, Geusens P, Pascale P, Delicha EM, Pricop L, Mpofu S (2016)

Publication Type: Conference contribution

Publication year: 2016

Journal

Arthritis and Rheumatology Wiley

Book Volume: 68

Authors with CRIS profile

Hans Jürgen Rech Department of Medicine 3 – Rheumatology and Immunology

Involved external institutions

Hasselt University / Universiteit Hasselt BE Belgium (BE) Swedish Medical Center US United States (USA) (US) Monash University AU Australia (AU) UC San Diego School of Medicine US United States (USA) (US) Barts Health NHS Trust GB United Kingdom (GB) Novartis AG CH Switzerland (CH) Dallas VA Medical Center US United States (USA) (US)

How to cite

APA:

Mease, P.J., Kavanaugh, A., Reimold, A., Tahir, H., Rech, J., Hall, S.,... Mpofu, S. (2016). Secukinumab Provides Sustained Improvements in the Signs and Symptoms of Active Psoriatic Arthritis through 3 Years: Efficacy and Safety Results from a Phase 3 Trial.

MLA:

Mease, Philip J., et al. "Secukinumab Provides Sustained Improvements in the Signs and Symptoms of Active Psoriatic Arthritis through 3 Years: Efficacy and Safety Results from a Phase 3 Trial." 2016.

BibTeX: Download